From the beginning of the covid-19 pandemic, we have already tested approx. 2,500 patients as part of various research projects.

Despite the ongoing Covid-19 pandemic at the BRG facility, we are still active and with ongoing projects. We maintain constant contact with our patients who are open to participation in new research. In order to maintain appropriate prophylaxis and safety of the conducted projects we perform according to the highest standards, using instructions and procedures of the Ministry of Health, Sanitary-epidemiological station, WHO (World Health Organization) and EMA (European Medicines Agency).

We have already tested approximately 2,500 patients as part of various research projects. The safety of patients is supervised by qualified nurses, laboratory technicians, pharmacists and coordinators as well as recognized medical experts with many years of experience and knowledge. This confirm that our site is effective and efficient and able to provide rapid study start-up for trials research of various therapies even in challenging environment.

Go back

News

Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

BioResearch is following  new recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic..

Read more …

BRG update on COVID-19

Dear Investigators and Researchers.
In recent days, the whole world is providing heroic fight with the SARS-CoV-2 virus.

Read more …

International Clinical Trials Day

On 28th of June, 2019 we attended the annual conference on the occassion of International Clinical Trials Day titled "On the verge of changes".

Read more …

TransCelerate accreditation

To improve our trainings system, we joined „GCP Mutual Recognition Program" and were accredited by TransCelerate Biopharma Inc

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲